Leonardi, Giulia C <br/><br/>
Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.  [electronic resource] 

 -  Journal of immunotherapy (Hagerstown, Md. : 1997)   
 - 249-251 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1537-4513 
<br/><br/><label>Standard No.: </label>10.1097/CJI.0000000000000173  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Autoantibodies--blood<br/>Carcinoma, Non-Small-Cell Lung--complications<br/>Diabetic Ketoacidosis--diagnosis<br/>Drug-Related Side Effects and Adverse Reactions--diagnosis<br/>Glutamate Decarboxylase--immunology<br/>Humans<br/>Immunotherapy--adverse effects<br/>Insulin--therapeutic use<br/>Lung Neoplasms--complications<br/>Male<br/>Programmed Cell Death 1 Receptor--immunology<br/>Remission Induction